An Open-Label Study Of Poly I:Poly C12U (AMPLIGEN) in Patients With Severely Debilitating Chronic Fatigue Syndrome (CFS)
Latest Information Update: 15 Apr 2024
At a glance
- Drugs Rintatolimod (Primary)
- Indications Chronic fatigue syndrome; Encephalomyelitis
- Focus Expanded access; Therapeutic Use
- Sponsors AIM ImmunoTech
- 15 Nov 2022 According to an AIM ImmunoTech media release, the company has enrolled five post-COVID patients with new onset ME/CFS following acute COVID-19.
- 28 Jul 2022 Interim results published in an AIM ImmunoTech Media Release.
- 18 May 2022 Results presented in an AIM ImmunoTech media release.